Novartis India (Small Cap) Share Target 2024, 2025 To 2039
|
Novartis India Limited |
|||
|
Price: ₹672.25 | ||
| 52 Week Low: ₹537.00 52 Week High: ₹909.00 |
|||
| Market Capital: 1,747.7 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Novartis India Share Price Target For 2024
- 1.1.1: Novartis India Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Novartis India Share Price Target For 2025
- 1.2.1: Novartis India Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Novartis India Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Novartis India Brief Company Overview
- 4: Novartis India Financial Performance
- 4.0.1: Is Novartis India A Good Buy For Long Term?
To predict the Novartis India's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Novartis India Share Price Target For 2024
The line chart displays the monthly closing prices of Novartis India with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Novartis India shares in 2024, see the table below.
Novartis India Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 686.87 (+2.17%) | Price Action: 01 Jun 2023 High |
| 2024 Target 2 | 680.0 (+1.14%) | Price Action: Jan 2012 High |
| 2024 Target 1 | 672.25 (0.00%) | Fibonacci Extension Level 82.00% |
| Current Price | 672.25 | Novartis India's share price as of 06 Dec 2023 |
| Stop Loss 1 | 672.25 (0.00%) | Fibonacci Retracement Level 82.60% |
| Stop Loss 2 | 664.15 (-1.21%) | Price Action: 27 Dec 2022 High |
| Stop Loss 3 | 657.06 (-2.25%) | Price Action: 29 Dec 2022 High |
Short-Term Technical Outlook
Current Technical Position: Novartis India is showing mixed momentum signals near key moving averages.
Key Technical Level: The 25-day moving average at ₹672.25 serves as the nearest technical reference point.
Historical Returns: 3-month: NA | 6-month: NA | 1-year: NA
Novartis India Share Price Target For 2025
The line chart displays the monthly closing prices of Novartis India with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Novartis India shares in 2025, see the table below.
Novartis India Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 930.06 (+38.35%) | Price Action: Chart |
| 2025 Target 2 | 912.72 (+35.77%) | Price Action: Chart |
| 2025 Target 1 | 903.68 (+34.42%) | Fibonacci Extension Level 64.90% |
| Current Price | 672.25 | Novartis India's share price as of 06 Dec 2023 |
| Stop Loss 1 | 619.1 (-7.91%) | Price Action: Jun 2017 Low |
| Stop Loss 2 | 612.67 (-8.86%) | Price Action: May 2021 High |
| Stop Loss 3 | 606.3 (-9.82%) | Price Action: 25 Jan 2023 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Novartis India is currently trading at 36.4% of its 52-week range (₹537 - ₹909).
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: NA | 3-year: -6.84% | 5-year: +0.7%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Novartis India Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹672.25 | ||
| 2025 | ₹695.01 | +3.38% | ₹737.41 |
| 2026 | ₹728.22 | +4.77% | ₹755.91 |
| 2027 | ₹751.22 | +3.15% | ₹762.49 |
| 2028 | ₹770.54 | +2.57% | ₹782.10 |
| 2029 | ₹750.05 | -2.65% | ₹792.90 |
| 2030 | ₹764.16 | +1.88% | ₹811.39 |
| 2031 | ₹799.26 | +4.59% | ₹829.89 |
| 2032 | ₹823.10 | +2.98% | ₹835.45 |
| 2033 | ₹842.89 | +2.4% | ₹855.53 |
| 2034 | ₹819.17 | -2.81% | ₹866.88 |
| 2035 | ₹833.31 | +1.72% | ₹885.38 |
| 2036 | ₹870.30 | +4.43% | ₹903.87 |
| 2037 | ₹894.98 | +2.83% | ₹908.40 |
| 2038 | ₹915.23 | +2.26% | ₹928.96 |
| 2039 | ₹914.60 | -0.06% | ₹940.86 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Novartis India Brief Company Overview
Novartis India Limited: A Healthcare Leader in India Novartis India Limited, established in 1947 and headquartered in Mumbai, is a prominent healthcare company operating in India. As a subsidiary of the global healthcare giant Novartis AG, the company has gained a strong...
reputation for providing innovative therapeutic solutions. Novartis India's diverse product portfolio includes bone and pain products under the Voveran brand, transplantation immunology products under brands like Simulect and Certican, and neurosciences products under Tegrital and Exelon. This wide range of offerings caters to a variety of healthcare needs. The company's commitment to innovation and patient care is evident in its research and development efforts. With a focus on areas like cardiovascular health, cancer, and neurology, Novartis India strives to develop and deliver cutting-edge treatments to patients.Novartis India Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 1,747.7 Crore | Market valuation of Novartis India's shares. |
| Revenue (TTM) | 345.1 Crore | Total revenue generated by Novartis India over the past twelve months. |
| Net Income (TTM) | +87.4 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +26.15% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +25.32% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+10.6% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
-13.8% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
0.82 | Company's total debt divided by total shareholder equity. |
| Total Debt | 6.03 Crore | Sum of Novartis India's current & long-term financial obligations. |
| Total Cash | 597.24 Crore | Total amount of liquid funds available to Novartis India. |
| Beta | 0.3 | Beta is less than 1 indicating that the Novartis India's price is less volatile than the market. |
Is Novartis India A Good Buy For Long Term?
No valid response content found
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
